BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

It would be important to incentivise investments in R&D for India: Boehringer Ingelheim India

25 January 2022 | Views

Vani Manja, Country Managing Director,Â Boehringer Ingelheim India



"The increased allocation of funds in last year's budget alongside the recent commitment of Rs 64,000 crores towards healthcare over the next five years is a testament to the government's focus on strengthening the health infrastructure in the country. I expect this will be reflected in the upcoming budget as well. What will be critical to ensure is not only increased expenditure towards healthcare but also a well-planned and balanced allocation coupled with a strong execution roadmap that addresses areas beyond COVID-19 to secure long-term sustainable impact. Specifically, the burden on the healthcare infrastructure caused by the increasing burden of NCDs should continue to be considered. It would also be important to incentivise investments in R&D for India to become an attractive innovation hub and maximize access to innovation for patients in India."